Dippel DW et al. |
What is the lowest dose of aspirin for maximum suppression of in vivo thromboxane production after a transient ischemic attack or ischemic stroke? |
2004 |
Cerebrovasc. Dis. |
pmid:15026612
|
Capone ML et al. |
Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. |
2004 |
Circulation |
pmid:15037526
|
Leonhardt A et al. |
Reference intervals and developmental changes in urinary prostanoid excretion in healthy newborns, infants and children. |
1992 |
Acta Paediatr. |
pmid:1511190
|
Suzuki N et al. |
Quantitative liquid chromatography-tandem mass spectrometric analysis of 11-dehydro TXB2 in urine. |
2004 |
Prostaglandins Other Lipid Mediat. |
pmid:15165035
|
Riutta A et al. |
Solid-phase extraction of urinary 11-dehydrothromboxane B2 for reliable determination with radioimmunoassay. |
1992 |
Anal. Biochem. |
pmid:1519756
|
Ferroni P et al. |
Platelet activation in type 2 diabetes mellitus. |
2004 |
J. Thromb. Haemost. |
pmid:15304032
|
Perneby C et al. |
Prothrombotic responses to exercise are little influenced by clopidogrel treatment. |
2004 |
Thromb. Res. |
pmid:15381386
|
Hennekens CH et al. |
Terms and conditions: semantic complexity and aspirin resistance. |
2004 |
Circulation |
pmid:15381661
|
Rebuzzi AG et al. |
Importance of reperfusion on thromboxane A2 metabolite excretion after thrombolysis. |
1992 |
Am. Heart J. |
pmid:1539506
|
Davì G et al. |
Helicobacter pylori infection causes persistent platelet activation in vivo through enhanced lipid peroxidation. |
2005 |
Arterioscler. Thromb. Vasc. Biol. |
pmid:15472127
|